ProCE Banner Activity

Study 1503: Moxetumomab Pasudotox in Heavily Pretreated Relapsed/Refractory Hairy Cell Leukemia

Slideset Download
This CD22-targeted antibody–drug conjugate induced deep and durable responses in a heavily pretreated patient population with HCL.

Released: June 05, 2018

Expiration: June 04, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen